Pertussis Vaccine Trials: Symposium at the Istituto Superiore Di Sanita, Rome, October/November 1995 Book

	Pertussis: A Worldwide Problem	3
	Epidemiological Determinants of Pertussis	15
	The United States Research Strategy on Pertussis	25
	European Union Research Strategies on Vaccines	29
	Severe Adverse Events in the Italian and Stockholm I Pertussis Vaccine Clinical Trials	77
	Severe Adverse Events in a Comparative Efficacy Trial in Germany in Infants Receiving either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP (DTP) or DT Vaccine	83
	The Senegal Pertussis Trial: Safety and Surveillance of Adverse Reactions	91
	Safety Evaluation of One Whole-Cell and Three Acellular Pertussis Vaccines in Stockholm Trial II	99
	Hypotonic Hyporesponsive Episodes in Eight Pertussis Vaccine Studies	101
	Common Side Effects in the Italian and Stockholm I Trials	105
	Adverse Reactions of a Pertussis Toxoid Vaccine in a Double-Blind Placebo-Controlled Trial	109
	Minor Adverse Events in a Comparative Efficacy Trial in Germany in Infants Receiving Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP (DTP) or DT Vaccine	113
	Rapporteur's Summary	119
	Implications of Different Study Designs for the Evaluation of Acellular Pertussis Vaccines	123
	Case Definitions	135
	Preparation and Composition of Acellular Pertussis Vaccines. Consideration of Potential Effects on Vaccine Efficacy	143
	Absolute Efficacy of Acellular Pertussis Vaccines in Household Settings	153
	Estimation of Pertussis Vaccine Efficacy in the Presence of Covariates in Three Randomized Trials	161
	Absolute and Relative Efficacy of Whole-Cell Vaccines	167
	The Effectiveness of Whole-Cell Pertussis Vaccines	171
	Factors Influencing the Analysis of Secondary Prevention of Pertussis	175
	The Role of Bordetella pertussis Infections in Adults in the Epidemiology of Pertussis	181
	Rapporteurs' Summary	187
	A Comparison of Enzyme Immuno-Assays Used to Measure Serum Antibodies to Components of Bordetella pertussis	197
	Diagnostic Pertussis Serology in the Recent Clinical Efficacy Studies of Acellular Vaccines	205
	Serological Responses to Infection with B. pertussis	213
	Differences by Antigen in Seroconversion: Sensitivity, Specificity and Bias in the Serological Confirmation of Pertussis	221
	Rapporteur's Summary	229
	Isolation, Identification and Characterization of Bordetella pertussis	233
	Bordetella pertussis Serotype of Clinical Isolates in Sweden During 1970-1995 and Influence of Vaccine Efficacy Studies	239
	Diagnostic Polymerase Chain Reaction	247
	Bordetella parapertussis Infections	255
	Rapporteur's Summary	261
	Comparison of Serological Results in the NIAID Multicenter Acellular Pertussis Trial with Recent Efficacy Trials	265
	Antibody Kinetics and Long-Term Sero-Prevalence in the Italian Clinical Trial of Acellular Pertussis Vaccines	275
	Factors Influencing Antibody Responses to Acellular Pertussis Vaccines	279
	Methods for Estimating Serological Correlates of Protection	283
	Bortetella pertussis-Specific Th1/Th2 Cells Generated Following Respiratory Infection or Immunization with an Acellular Vaccine: Comparison of the T Cell Cytokine Profiles in Infants and Mice	297
	Cell-Mediated Immunity after Pertussis Vaccination and after Natural Infection	307
	Acellular Vaccines Induce Cell-Mediated Immunity to Bordetella pertussis Antigens in Infants Undergoing Primary Vaccination Against Pertussis	315
	Examination of Similarities between Diphtheria and Pertussis and their Toxoids Provide Insight into Vaccine-Induced Protection to Bordetella pertussis	321
	Japanese Experience with 60 Million Doses of Acellular Pertussis Vaccines	327
	Epidemiology of Pertussis and Use of Acellular Pertussis Vaccines in Japan	331
	Rapporteur's Summary	333
	Regulatory Issues Concerning Pertussis Vaccines	341
	A Consideration of Control Requirements for Acellular Pertussis Vaccines	343
	Regulatory and Standardization Issues	349
	Rapporteur's Summary	351
	Public Health Application of Acellular Pertussis Vaccines	355
	Acellular Pertussis Vaccines: The Next Step	363
	Public Health Implications: United Kingdom	367
	Rapporteur's Summary	369
	Safety of Acellular Pertussis Vaccine: Follow-up Studies	373
	Issues Regarding Future Research on Pertussis Vaccines	377
	Are Serological Responses to Acellular Pertussis Antigens Sufficient Criteria to Ensure that New Combination Vaccines are Effective for Prevention of Disease?	379
	Some Thoughts for Future Pertussis Research in Europe	391
	Rapporteur's Summary	393
	Rapporteur's Summary of the Symposium	397